The above information was disclosed in a filing to the SEC. Some additional info was provided as follows:
On December 14, 2012, Mr. Gregg adopted a 10b5-1 Plan. Under this 10b5-1 Plan, Mr. Gregg will sell a limited number of shares to cover the tax liability that accrues upon monthly vesting of restricted stock units previously granted to Mr. Gregg. The shares set forth above were sold pursuant to the 10b5-1 Plan.
This transaction was executed in multiple trades at prices ranging from $22.55 to $23.06. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected.
Included in this number are 106,641 unvested restricted stock units granted on March 8, 2012, 5,078 of which shall vest each month through March 8, 2015 and 45,704 unvested restricted stock units granted on March 8, 2011, 5,078 of which shall vest each month through March 8, 2014.
Shares are held by the Gregg Family Trust U/A/D 12/23/1998, with respect to which the reporting person is a trustee.
To see this filing in its entirety, click here
To receive a free e-mail notification whenever an insider of DexCom makes a similar move, sign up!
Other recent filings from the company include the following:
Other definitive proxy statements - April 16, 2014
Additional definitive proxy soliciting materials and Rule 14(a)(12) material - April 16, 2014
DexCom's CEO just disposed of 10,000 shares - April 16, 2014
Sr. VP of DexCom just disposed of 1,134 shares - April 16, 2014
SVP of DexCom just cashed-in 10,000 options - April 15, 2014